Therapeutic options in patients with biochemical recurrence after radical prostatectomy (Review)

Bratu, Ovidiu Gabriel; Mischianu, Dan; Constantin, Traian; Stănescu, Ana Maria Alexandra; Bungău, Simona; Ioniţă-Radu, Florentina; Marcu, Radu Dragos

doi:10.3892/etm.2019.7916

Cited by 6 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although vitamin D levels are associated with increased MS, the role of supplement doses should be further investigated (30). Difficulties in supporting differential diagnosis, or in the medical or surgical approach of patients with chronic neoplastic conditions are inherent (31)(32)(33)(34), but early detection and intervention increase survival and quality of life.…”

Section: Discussionmentioning

confidence: 99%

Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report

et al. 2020

View full text Add to dashboard Cite

The role of interferon β-1b , used for multiple sclerosis (MS) therapy, in cancer occurrence is uncertain. There is evidence supporting the role of human herpesvirus 4 [Epstein-Barr virus (EBV)] in thyroid cancer and MS. Simultaneous occurrence of papillary and medullary carcinomas is rare, and its association with MS in a young woman raises questions. A 46-year-old female patient was diagnosed with relapsing-remitting multiple sclerosis in 2008. In 2018, cervical MRI detected a thyroid nodule with right cervical adenopathy. Her thyroid function was normal, but increased calcitonin levels were found (70.53 pg/ml; normal value: <9.82 pg/ml). EBV serology tested positive. Paraclinical studies ruled out multiple endocrine neoplasia syndrome. Whole thyroid resection with whole cervical lymph node dissection was performed. To our knowledge, this is the first case that describes an association between MS and thyroid collision tumors. Histological examination ascertained both papillary and medullary thyroid cancer. After surgery, the calcitonin level normalized, and the patient received a therapeutic dose of iodine-131. IFNβ-1b therapy was discontinued. The coexistence of thyroid cancers in MS patients could be explained by immune-mediated inflammation. Although EBV is not the only agent responsible for the development of MS or thyroid cancers, it could be considered a contributory factor in our case. Further research on EBV involvement in the occurrence of simultaneous immune pathologies in various organs is needed to confirm these data.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Radical prostatectomy is the treatment method most frequently applied to patients who have prostate cancer clinically restricted to the organ and have a life expectancy of >10 years (9). In the follow-up period following RP, BR develops in 20%-30% of patients with increased PSA without any clinical or radiological findings of metastasis (10,11). BR develops in the early period, within the first two years after RP, in approximately two-thirds of patients (12,13).…”

Section: Discussionmentioning

confidence: 99%

The relationship between the CAPRA-S and the time of biochemical recurrence following radical prostatectomy

Tagci¹,

Özden²,

Kızılkan³

et al. 2021

New J Urol.

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate the relationship between biochemical recurrence time and the “cancer of the prostate risk assessment post-surgery” score (CAPRA-S) after radical prostatectomy (RP). Material and Methods: Retrospective evaluation was made of the records of 328 patients applied with RP for a diagnosis of clinically localized prostate cancer. The patients were separated into groups according to the CAPRA-S score determined according to the preoperative PSA level and pathological characteristics of the RP specimen and the biochemical recurrence time after RP. Results: The mean follow-up period was 76.9±34.5 months. Biochemical recurrence was determined in 23.2% (n:69) of the cases, as early recurrence in 71% (n:49) and late in 29% (n:20). According to the CAPRA-S score, 186 (62.4%) patients were classified as low risk, 66 (22.1%) as moderate risk, and 46 (15%) as high risk. The 3 and 5-year BRFS rates of all the patients were 88.9% and 81.8% respectively. Patients with a low CAPRA-S score were determined to have a statistically significantly higher 3 and 5-year BRFS rate than patients in the moderate and high groups. Early biochemical recurrence after RP was statistically significantly correlated only with lymph node involvement (OR: 2.42, 95% CI: 1.07-5.47, p=0.03). Conclusion: This study showed that the CAPRA-S score, which is effective in predicting the risk of biochemical recurrence after RP, was not effective in predicting the time of biochemical recurrence after RP. Keywords: Biochemical recurrence, CAPRA-S score, prostate cancer, radical prostatectomy

show abstract

“…This procedure offers good results in terms of disease-free survival and overall survival, but like any other major surgical procedures, this also presents several possible disadvantages, such as postoperative erectile dysfunction (ED) and urinary incontinence. Because the mean age for the time of diagnosis has decreased, postoperative erectile function (EF) recovery represents an important issue among urologists (2,3).…”

Section: Introductionmentioning

confidence: 99%

Benefits of erectile function recovery programs after radical prostatectomy (Review)

Marcu¹,

Lorga²,

Diaconu

et al. 2020

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

Radical prostatectomy is one of the most frequent therapeutic options used for the management of patients diagnosed with prostate cancer. Normal erectile function after radical prostatectomy is a great problem for numerous patients and a real challenge for urologists worldwide. The advancements that have been made over the years in terms of minimally invasive surgery, as well as in terms of surgical techniques, have reduced the incidence of erectile dysfunction, but even so, its rate remains high and the post-operative recovery of erectile function is a long and costly process. Phosphodiesterase 5 inhibitors have provided excellent results and have become the first-line treatment for these patients, followed by intracavernous injections with alprostadil. Several studies have underlined the impact of phosphodiesterase 5 inhibitors in terms of preventing the fibrotic changes that are responsible for the irreversible erectile dysfunction. The general opinion is that an erectile function recovery process should be started as soon as possible after surgery to prevent the negative effects of neuropraxia. Contents 1. Introduction 2. Erectile dysfunction pathophysiology 3. The role of phosphodiesterase 5-inhibitors in erectile function recovery 4. Discussion

show abstract

Therapeutic options in patients with biochemical recurrence after radical prostatectomy (Review)

Cited by 6 publications

References 38 publications

Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report

Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report

The relationship between the CAPRA-S and the time of biochemical recurrence following radical prostatectomy

Benefits of erectile function recovery programs after radical prostatectomy (Review)

Contact Info

Product

Resources

About